Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Single-center, Open-label, Single Dose, Two-period, Crossover Study to Investigate the Relative Bioavailability of Binimetinib 3 x15 mg and 45 mg Tablets in Healthy Participants

NCT05103891 is registered in ClinicalTrials.gov with Pierre Fabre Medicament as lead sponsor.

NCT NCT05103891
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05103891 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Single-center, Open-label, Single Dose, Two-period, Crossover Study to Investigate the Relative Bioavailability of Binimetinib 3 x15 mg and 45 mg Tablets in Healthy Participants
Lead sponsor
Pierre Fabre Medicament
Phase
Phase 1
Overall status
Unknown status
Start date
September 3, 2021
Completion date
November 29, 2021
Enrollment
14 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

braf v600 mutation, melanoma, metastatic melanoma, unresectable melanoma